The tumor suppressor kallikrein-related peptidase 6 (KLK6), is inactivated in metastatic breast-cancer cells, and studies have underscored the role of MeCP2 in silencing the KLK6 gene in metastatic breast cancer. Here, KLK6 is linked to breast carcinoma.